Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (473)	6/9/1998 10:14:00 PM
From: David M. Evans	Respond to of 705

You are very tolerant and IMHO, too kind, in your response to such posts <g> Mother used to tell me that where ignorance was bliss, it was folly to be wise ... Thanks for your contributions to this thread - I for one, and I know many others, respect your opinion on this stock.

To: NeuroInvestment who wrote (473)	6/9/1998 11:38:00 PM
From: Joe Bz	Respond to of 705

You guys are in denial. Neuroinvestor why can't you accept the fact that Glasky made some misleading and factually inaccurate statements about the company that he and his family own and run. As a consequence of his statements NEOT made a spectacular one day run from single digits to over 20. The stock went up about 150% in a matter of hours, only to fall by over 8 points the next day after his statements were corrected by the company. Please do not try to deny these facts by passing it off as just a little over enthusiasm or too much wine. Which is what you did in some of your past posts. I feel sorry for those that bought at the top. They have lost a lot of money. Glasky's behavior demonstrated that 1)he either does not understand what is going on in his company or 2) he was hyping it. His behavior also prompted several news sources (such as Motley Fool) to dredge up his less than ideal past relationship with the FDA. Not knowing what is going on in this tiny company is a fatal flaw in my opinion. Additionally, having so many family members in such important roles should be a serious warning flag to all investors. I would not make a long term investment in NEOT because of these facts. If Glasky was hyping, the legal ramifications could be staggering to NEOT and all of its investors. NEOT would not be able to afford the legal bills to defend itself. I am glad to see you factored dilution into your model of NEOT. Perhaps you would care to share this aspect of your analysis. Just how many more shares of NEOT stock do you think will be issued before a marketable drug is developed and approved by the FDA? I think the equity line of credit is bs and will probably never be used. I expect a secondary offer to be done to raise additional cash. What do you think?